Form 4: Voyager Therapeutics Director Granted Stock Options
Statement of Changes in Beneficial Ownership
Voyager Therapeutics reports the grant of stock options to Director Glenn Pierce under the company's 2025 Stock Incentive Plan.
Summary
- Director Glenn Pierce was granted 30,000 stock options with an exercise price of $3.43.
- The options were granted on June 9, 2026, under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.
- These options are part of the company's director compensation policy.
- The options vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, contingent on continued service as a director.
- The filing also includes a Power of Attorney appointing representatives to handle SEC filings on behalf of Glenn Pierce.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.
Positives
- Grant of stock options to a director, indicating potential alignment of management and shareholder interests.
- The options are granted under an existing incentive plan, suggesting established compensation structures.
- Vesting conditions tied to continued service and annual meetings promote long-term commitment.
Risks
- The value of the stock options is subject to the future performance of Voyager Therapeutics' stock price.
- Continued service as a director is a condition for vesting, meaning any departure before the vesting date would forfeit the options.
Future Outlook
The future outlook for the stock options is dependent on the company's performance and stock price appreciation. The vesting schedule indicates a one-year horizon for partial vesting and potential full vesting at the next annual meeting.
Industry Context
StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to incentivize leadership and align their financial interests with those of shareholders, especially in companies focused on long-term development and clinical trials.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Glenn Pierce has granted a Power of Attorney to specific individuals to act on his behalf for SEC filings, including Forms 3, 4, 5, Schedules 13D/13G, and Forms 144, related to his role as an officer, director, or stockholder of Voyager Therapeutics, Inc. | May 29, 2026 | Facilitates efficient and timely compliance with SEC reporting requirements for beneficial ownership and transactions. |
Stakeholder Impact
- Shareholders: The grant of options to a director aligns incentives, but the ultimate impact depends on the company's stock performance.
- Employees: This filing does not directly impact employees but is part of the broader compensation structure for key personnel.
- Management: Reinforces the compensation framework for directors.
Next Steps
- Glenn Pierce must continue his service as a director for the stock options to vest.
- The stock options will expire on June 9, 2036, if not exercised.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of stock option grant and earliest transaction date. |
| 06/11/2026 | Date of signature for the Power of Attorney. |
| 06/09/2036 | Expiration date of the granted stock options. |
Keywords
Voyager Therapeutics, VYGR, Form 4, Stock Options, Director Compensation, SEC Filing, Glenn Pierce, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.